Loading Events

Dr. Tim Triche Jr. is seeking a full-time Computational Biologist to join his research team. The Triche Lab focuses on developing statistical and mathematical methods to dissect pediatric and adult cancers, with a focus on cancers of the blood in children. In pediatric tumors, recurrent mutations alone are rarely sufficient to characterize a person’s disease, and the role of inherited susceptibility is poorly understood. The lab seeks to improve both outcomes and quality of life by rational selection of positive (“Patients with X usually respond to A”) biomarkers for response and negative (“Patients with Y rarely respond to B”) biological markers for non-response over the course of disease. Particularly in rare tumors, this approach is well suited to rapidly piloting clinical trials and re-purposing existing drugs; indeed, one such regional DNA methylation marker is currently in a Phase III trial for front-line chemotherapy.

We collaborate broadly with clinical and basic scientists. The role of chromatin- and DNA-modifying proteins, under the catchall term epigenetic regulators, is a primary interest. Recent work characterizing genetic influences on transcription suggests that rare variants dominate the landscape, motivating an alternate readout of regulatory aberrations. We are developing methods to improve both variant prioritization and interpretation of regulatory impacts by jointly analyzing both. To do so, we make heavy use of high-throughput sequence analysis, both in bulk and sorted cells, often from clinical trials.

Ours is a young lab. You will help determine its growth and direction, and it will help determine yours.

In this role, you will be responsible for the following tasks:

  • Handle data management and reproducible analysis for a variety of experimental designs
  • Develop, maintain, and support computational biology pipelines
  • Perform data mining at scale on both local and (where feasible) cloud pilot resources
  • Pre-print and publish results and novel methods, serving as primary or contributing author, while ensuring compliance with data sharing plans, and wherever possible, unsupervised replication
  • Anticipate and keep abreast of new developments in bioinformatics and works to ensure the availability of state-of-the-art methods, resources, and data sources to support the user groups
  • Perform other related duties as assigned (to include wet protocols if suited to the candidate)

This list will likely change as projects evolve and you must be open-minded to learn new things.

Expectations:

The following expectations should be met within the first 3 months.

  • 1 month – Develop solid understanding of at least one major collaborative project, adapt to VAI computing resources, and demonstrate analytical reproducibility, supervised by a senior collaborator
  • 3 months – Acquire significant data, prepare informative summaries of interim analyses, and take over both maintenance and development of analytical pipelines from our senior collaborators.

Qualifications:

You will possess a Master’s degree in computational biology, bioinformatics, mathematics, statistics, computer science, or other relevant discipline (a BS with experience will be considered).

The ideal candidate

  • Has working knowledge of at least one scripting language (e.g. R) and systems language (e.g. C)
  • Has substantial experience with the analysis of next generation sequencing data (e.g. RNAseq)
  • Has experience, or interest in gaining experience, with data integration (e.g. ATAC, WGBS, Hi-C)
  • Has an understanding of cancer biology or genetics; this is helpful but not absolutely required.
  • May see this position as an ideal launching point for further graduate or clinical studies.
  • Has a commitment to open, collegial, reproducible science, and the betterment of society.

If you possess these attributes and desire to help us drive science from the bench to the clinic, while benefiting from a highly generous compensation package; we would welcome speaking with you and encourage you to apply today.

Share This Story, Choose Your Platform!